https://stock.noler.com/us/stock/gsk https://stock.noler.com/us/stock/gsk/13f-holdings https://stock.noler.com/us/stock/gsk/accruals https://stock.noler.com/us/stock/gsk/accruals-and-deferred-income https://stock.noler.com/us/stock/gsk/accrued-income https://stock.noler.com/us/stock/gsk/accrued-income-other-than-contract-assets https://stock.noler.com/us/stock/gsk/acquisitiondate-fair-value-of-total-consideration-transferred https://stock.noler.com/us/stock/gsk/acquisitions-through-business-combinations-other-provisions https://stock.noler.com/us/stock/gsk/acquisitions-through-business-combinations-rightofuse-assets https://stock.noler.com/us/stock/gsk/activist-13d-13g https://stock.noler.com/us/stock/gsk/actuarial-assumption-of-discount-rates https://stock.noler.com/us/stock/gsk/actuarial-gains-losses-arising-from-changes-in-demographic-assumptions-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/gsk/actuarial-gains-losses-arising-from-changes-in-financial-assumptions-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/gsk/actuarial-gains-losses-arising-from-experience-adjustments-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/gsk/additional-provisions-other-provisions https://stock.noler.com/us/stock/gsk/additional-recognition-goodwill https://stock.noler.com/us/stock/gsk/additions-other-than-through-business-combinations-rightofuse-assets https://stock.noler.com/us/stock/gsk/additions-to-rightofuse-assets https://stock.noler.com/us/stock/gsk/adjusted-weighted-average-shares https://stock.noler.com/us/stock/gsk/adjustments-for-amortisation-expense https://stock.noler.com/us/stock/gsk/adjustments-for-current-tax-of-prior-period https://stock.noler.com/us/stock/gsk/adjustments-for-decrease-increase-in-inventories https://stock.noler.com/us/stock/gsk/adjustments-for-decrease-increase-in-other-operating-receivables https://stock.noler.com/us/stock/gsk/adjustments-for-decrease-increase-in-trade-account-receivable https://stock.noler.com/us/stock/gsk/adjustments-for-depreciation-expense https://stock.noler.com/us/stock/gsk/adjustments-for-fair-value-gains-losses https://stock.noler.com/us/stock/gsk/adjustments-for-finance-income-cost https://stock.noler.com/us/stock/gsk/adjustments-for-gain-loss-on-disposal-of-investments-in-subsidiaries-joint-ventures-and-associates https://stock.noler.com/us/stock/gsk/adjustments-for-income-tax-expense https://stock.noler.com/us/stock/gsk/adjustments-for-increase-decrease-in-employee-benefit-liabilities https://stock.noler.com/us/stock/gsk/adjustments-for-increase-decrease-in-other-operating-payables https://stock.noler.com/us/stock/gsk/adjustments-for-increase-decrease-in-trade-account-payable https://stock.noler.com/us/stock/gsk/adjustments-for-reconcile-profit-loss https://stock.noler.com/us/stock/gsk/adjustments-for-share-based-payments https://stock.noler.com/us/stock/gsk/advertising-expense https://stock.noler.com/us/stock/gsk/amended-reports-10-k https://stock.noler.com/us/stock/gsk/amortisation-intangible-assets-other-than-goodwill https://stock.noler.com/us/stock/gsk/analyst-ratings-buy https://stock.noler.com/us/stock/gsk/analyst-ratings-hold https://stock.noler.com/us/stock/gsk/analyst-ratings-no-rating https://stock.noler.com/us/stock/gsk/analyst-ratings-sell https://stock.noler.com/us/stock/gsk/applicable-tax-rate https://stock.noler.com/us/stock/gsk/auditor https://stock.noler.com/us/stock/gsk/auditors-remuneration https://stock.noler.com/us/stock/gsk/auditors-remuneration-for-audit-services https://stock.noler.com/us/stock/gsk/auditors-remuneration-for-other-services https://stock.noler.com/us/stock/gsk/auditors-remuneration-for-tax-services https://stock.noler.com/us/stock/gsk/average-effective-tax-rate https://stock.noler.com/us/stock/gsk/average-number-of-employees https://stock.noler.com/us/stock/gsk/bank-overdrafts-classified-as-cash-equivalents https://stock.noler.com/us/stock/gsk/basic-earnings-loss-per-share https://stock.noler.com/us/stock/gsk/basic-earnings-loss-per-share-from https://stock.noler.com/us/stock/gsk/basic-earnings-loss-per-share-from-discontinued-operations https://stock.noler.com/us/stock/gsk/borrowings https://stock.noler.com/us/stock/gsk/brand-names https://stock.noler.com/us/stock/gsk/business https://stock.noler.com/us/stock/gsk/buybacks https://stock.noler.com/us/stock/gsk/capitalisation-rate-of-borrowing-costs-eligible-for-capitalisation https://stock.noler.com/us/stock/gsk/cash https://stock.noler.com/us/stock/gsk/cash-and-cash-equivalents https://stock.noler.com/us/stock/gsk/cash-and-cash-equivalents-classified-as-part-of-disposal-group-held-for-sale https://stock.noler.com/us/stock/gsk/cash-and-cash-equivalents-held-by-entity-unavailable-for-use-by-group https://stock.noler.com/us/stock/gsk/cash-and-cash-equivalents-if-different-from-statement-of-financial-position https://stock.noler.com/us/stock/gsk/cash-and-cash-equivalents-recognised-as-of-acquisition-date https://stock.noler.com/us/stock/gsk/cash-equivalents https://stock.noler.com/us/stock/gsk/cash-flow-breakdown https://stock.noler.com/us/stock/gsk/cash-flows-from-losing-control-of-subsidiaries-or-other-businesses-classified-as-investing-activities https://stock.noler.com/us/stock/gsk/cash-flows-from-used-in-financing-activities https://stock.noler.com/us/stock/gsk/cash-flows-from-used-in-financing-activities-discontinued-operations https://stock.noler.com/us/stock/gsk/cash-flows-from-used-in-financing-activities-ifrs-full https://stock.noler.com/us/stock/gsk/cash-flows-from-used-in-increase-decrease-in-current-borrowings https://stock.noler.com/us/stock/gsk/cash-flows-from-used-in-investing-activities https://stock.noler.com/us/stock/gsk/cash-flows-from-used-in-investing-activities-discontinued-operations https://stock.noler.com/us/stock/gsk/cash-flows-from-used-in-investing-activities-ifrs-full https://stock.noler.com/us/stock/gsk/cash-flows-from-used-in-operating-activities https://stock.noler.com/us/stock/gsk/cash-flows-from-used-in-operating-activities-discontinued-operations https://stock.noler.com/us/stock/gsk/cash-flows-from-used-in-operating-activities-ifrs-full https://stock.noler.com/us/stock/gsk/cash-flows-from-used-in-operations https://stock.noler.com/us/stock/gsk/cash-flows-used-in-obtaining-control-of-subsidiaries-or-other-businesses-classified-as-investing-activities https://stock.noler.com/us/stock/gsk/cash-outflow-for-leases https://stock.noler.com/us/stock/gsk/cash-transferred https://stock.noler.com/us/stock/gsk/clinical-trials https://stock.noler.com/us/stock/gsk/commercial-paper-average-rate-paid https://stock.noler.com/us/stock/gsk/commercial-papers-issued https://stock.noler.com/us/stock/gsk/company-guidance https://stock.noler.com/us/stock/gsk/company-profile https://stock.noler.com/us/stock/gsk/comprehensive-income https://stock.noler.com/us/stock/gsk/comprehensive-income-attributable-to-noncontrolling-interests https://stock.noler.com/us/stock/gsk/comprehensive-income-attributable-to-owners-of-parent https://stock.noler.com/us/stock/gsk/comprehensive-income-from https://stock.noler.com/us/stock/gsk/comprehensive-income-from-discontinued-operations https://stock.noler.com/us/stock/gsk/congressional-trades-stocks-including-adrs https://stock.noler.com/us/stock/gsk/contingent-consideration-recognised-as-of-acquisition-date https://stock.noler.com/us/stock/gsk/contingent-liabilities-recognised-in-business-combination https://stock.noler.com/us/stock/gsk/contingent-rents-recognised-as-expense-classified-as-operating-lease https://stock.noler.com/us/stock/gsk/contract-liabilities https://stock.noler.com/us/stock/gsk/contractual-commitments-for-acquisition-of-intangible-assets https://stock.noler.com/us/stock/gsk/contractual-commitments-for-acquisition-of-property-plant-and-equipment https://stock.noler.com/us/stock/gsk/contributions-to-plan-by-employer-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/gsk/convertible-securities-retired https://stock.noler.com/us/stock/gsk/cost-of-inventories-recognised-as-expense https://stock.noler.com/us/stock/gsk/cost-of-sales https://stock.noler.com/us/stock/gsk/cover-page-shares-outstanding https://stock.noler.com/us/stock/gsk/current-and-deferred-tax-relating-to-items-charged-or-credited-directly-to-equity https://stock.noler.com/us/stock/gsk/current-assets https://stock.noler.com/us/stock/gsk/current-assets-other-than-assets-or-disposal-groups-classified-as-held-for-sale-or-as-held-for-distribution-to-owners https://stock.noler.com/us/stock/gsk/current-derivative-financial-assets https://stock.noler.com/us/stock/gsk/current-derivative-financial-liabilities https://stock.noler.com/us/stock/gsk/current-financial-assets-at-fair-value-through-profit-or-loss-classified-as-held-for-trading https://stock.noler.com/us/stock/gsk/current-lease-liabilities https://stock.noler.com/us/stock/gsk/current-liabilities https://stock.noler.com/us/stock/gsk/current-payables-on-social-security-and-taxes-other-than-income-tax https://stock.noler.com/us/stock/gsk/current-ratio https://stock.noler.com/us/stock/gsk/current-raw-materials-and-current-production-supplies https://stock.noler.com/us/stock/gsk/current-service-cost-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/gsk/current-tax-assets https://stock.noler.com/us/stock/gsk/current-tax-expense-income-and-adjustments-for-current-tax-of-prior-periods https://stock.noler.com/us/stock/gsk/current-tax-expense-income-related-to-pillar-two-income-taxes https://stock.noler.com/us/stock/gsk/current-tax-liabilities https://stock.noler.com/us/stock/gsk/current-tax-liabilities-noncurrent https://stock.noler.com/us/stock/gsk/current-tax-relating-to-items-charged-or-credited-directly-to-equity https://stock.noler.com/us/stock/gsk/debt-equity-ratio https://stock.noler.com/us/stock/gsk/debt-securities https://stock.noler.com/us/stock/gsk/decrease-increase-through-tax-on-share-based-payment-transactions https://stock.noler.com/us/stock/gsk/decrease-through-classified-as-held-for-sale-rightofuse-assets https://stock.noler.com/us/stock/gsk/decrease-through-transfer-to-liabilities-included-in-disposal-groups-classified-as-held-for-sale-other-provisions https://stock.noler.com/us/stock/gsk/deferred-income https://stock.noler.com/us/stock/gsk/deferred-income-classified-as-noncurrent https://stock.noler.com/us/stock/gsk/deferred-tax-assets https://stock.noler.com/us/stock/gsk/deferred-tax-expense-income https://stock.noler.com/us/stock/gsk/deferred-tax-expense-income-recognised-in-profit-or-loss https://stock.noler.com/us/stock/gsk/deferred-tax-liabilities https://stock.noler.com/us/stock/gsk/deferred-tax-liabilities-recognised-as-of-acquisition-date https://stock.noler.com/us/stock/gsk/deferred-tax-liability-asset https://stock.noler.com/us/stock/gsk/deferred-tax-relating-to-items-charged-or-credited-directly-to-equity https://stock.noler.com/us/stock/gsk/defined-benefit-obligation-at-present-value https://stock.noler.com/us/stock/gsk/depreciation-and-amortisation-expense https://stock.noler.com/us/stock/gsk/depreciation-property-plant-and-equipment https://stock.noler.com/us/stock/gsk/depreciation-rightofuse-assets https://stock.noler.com/us/stock/gsk/derivative-financial-assets https://stock.noler.com/us/stock/gsk/derivative-financial-assets-held-for-trading https://stock.noler.com/us/stock/gsk/derivative-financial-liabilities https://stock.noler.com/us/stock/gsk/derivative-financial-liabilities-held-for-trading https://stock.noler.com/us/stock/gsk/description-of-discount-rates-applied-to-cash-flow-projections https://stock.noler.com/us/stock/gsk/diluted-earnings-loss-per-share https://stock.noler.com/us/stock/gsk/diluted-earnings-loss-per-share-from https://stock.noler.com/us/stock/gsk/diluted-earnings-loss-per-share-from-discontinued-operations https://stock.noler.com/us/stock/gsk/dilutive-effect-of-share-options-on-number-of-ordinary-shares https://stock.noler.com/us/stock/gsk/disposals-property-plant-and-equipment https://stock.noler.com/us/stock/gsk/disposals-rightofuse-assets https://stock.noler.com/us/stock/gsk/distribution-costs https://stock.noler.com/us/stock/gsk/dividend https://stock.noler.com/us/stock/gsk/dividend-safety https://stock.noler.com/us/stock/gsk/dividends-paid https://stock.noler.com/us/stock/gsk/dividends-paid-classified-as-financing-activities https://stock.noler.com/us/stock/gsk/dividends-paid-ordinary-shares https://stock.noler.com/us/stock/gsk/dividends-paid-ordinary-shares-per-share https://stock.noler.com/us/stock/gsk/dividends-paid-to-equity-holders-of-parent-classified-as-financing-activities https://stock.noler.com/us/stock/gsk/dividends-paid-to-noncontrolling-interests-classified-as-financing-activities https://stock.noler.com/us/stock/gsk/dividends-received-classified-as-investing-activities https://stock.noler.com/us/stock/gsk/dividends-received-from-investments-accounted-for-using-equity-method-classified-as-investing-activities https://stock.noler.com/us/stock/gsk/dividends-recognised-as-distributions-to-noncontrolling-interests https://stock.noler.com/us/stock/gsk/ebitda https://stock.noler.com/us/stock/gsk/ebitda-margin https://stock.noler.com/us/stock/gsk/effect-of-exchange-rate-changes-on-cash-and-cash-equivalents https://stock.noler.com/us/stock/gsk/employee-benefits-expense https://stock.noler.com/us/stock/gsk/employee-count https://stock.noler.com/us/stock/gsk/equity https://stock.noler.com/us/stock/gsk/equity-and-liabilities https://stock.noler.com/us/stock/gsk/equity-attributable-to-owners-of-parent https://stock.noler.com/us/stock/gsk/estimated-financial-effect-of-contingent-liabilities https://stock.noler.com/us/stock/gsk/executive-pay-pvp https://stock.noler.com/us/stock/gsk/executive-salary-officers https://stock.noler.com/us/stock/gsk/expense-breakdown https://stock.noler.com/us/stock/gsk/expense-due-to-unwinding-of-discount-on-provisions https://stock.noler.com/us/stock/gsk/expense-from-share-based-payment-transactions-with-employees https://stock.noler.com/us/stock/gsk/expense-of-restructuring-activities https://stock.noler.com/us/stock/gsk/expense-relating-to-leases-of-lowvalue-assets-for-which-recognition-exemption-has-been-used https://stock.noler.com/us/stock/gsk/expense-relating-to-shortterm-leases-for-which-recognition-exemption-has-been-used https://stock.noler.com/us/stock/gsk/expense-relating-to-variable-lease-payments-not-included-in-measurement-of-lease-liabilities https://stock.noler.com/us/stock/gsk/finance-costs https://stock.noler.com/us/stock/gsk/finance-income https://stock.noler.com/us/stock/gsk/finance-lease-liabilities https://stock.noler.com/us/stock/gsk/financial-assets https://stock.noler.com/us/stock/gsk/financial-assets-at-fair-value https://stock.noler.com/us/stock/gsk/financial-assets-pledged-as-collateral-for-liabilities-or-contingent-liabilities https://stock.noler.com/us/stock/gsk/financial-assets-with-modified-contractual-cash-flows-while-loss-allowance-measured-at-lifetime-expected-credit-losses-for-which-loss-allowance-changed-during-reporting-period-to-12-month-expected-credit-losses-gross-carrying-amount https://stock.noler.com/us/stock/gsk/financial-instruments-designated-as-hedging-instruments-at-fair-value https://stock.noler.com/us/stock/gsk/financial-liabilities https://stock.noler.com/us/stock/gsk/financial-liabilities-at-fair-value https://stock.noler.com/us/stock/gsk/finished-goods https://stock.noler.com/us/stock/gsk/form-144-stocks https://stock.noler.com/us/stock/gsk/form-n-port-stocks https://stock.noler.com/us/stock/gsk/future-finance-charge-on-finance-lease https://stock.noler.com/us/stock/gsk/gain-loss-on-hedge-ineffectiveness-recognised-in-profit-or-loss https://stock.noler.com/us/stock/gsk/gain-loss-on-remeasurement-of-reimbursement-rights https://stock.noler.com/us/stock/gsk/gains-losses-arising-from-settlements-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/gsk/gains-losses-on-cash-flow-hedges-before-tax https://stock.noler.com/us/stock/gsk/gains-losses-on-cash-flow-hedges-net-of-tax https://stock.noler.com/us/stock/gsk/gains-losses-on-change-in-fair-value-of-derivatives https://stock.noler.com/us/stock/gsk/gains-losses-on-change-in-value-of-forward-elements-of-forward-contracts-net-of-tax https://stock.noler.com/us/stock/gsk/gains-losses-on-change-in-value-of-time-value-of-options-net-of-tax https://stock.noler.com/us/stock/gsk/gains-losses-on-disposals-of-investments https://stock.noler.com/us/stock/gsk/gains-losses-on-disposals-of-noncurrent-assets https://stock.noler.com/us/stock/gsk/gains-losses-on-exchange-differences-on-translation-before-tax https://stock.noler.com/us/stock/gsk/gains-losses-on-exchange-differences-on-translation-recognised-in-profit-or-loss https://stock.noler.com/us/stock/gsk/gains-losses-on-financial-assets-at-fair-value-through-profit-or-loss-mandatorily-measured-at-fair-value https://stock.noler.com/us/stock/gsk/gains-losses-on-financial-assets-measured-at-fair-value-through-oci-before-tax https://stock.noler.com/us/stock/gsk/gains-losses-on-financial-liabilities-at-fair-value-through-profit-or-loss https://stock.noler.com/us/stock/gsk/gains-losses-on-ineffectiveness-of-hedges-of-net-investments-in-foreign-operations https://stock.noler.com/us/stock/gsk/gains-losses-on-remeasuring-available-for-sale-financial-assets-before-tax https://stock.noler.com/us/stock/gsk/gains-losses-recognised-in-oci-fair-value-measurement-assets https://stock.noler.com/us/stock/gsk/gains-losses-recognised-in-profit-or-loss-fair-value-measurement-assets https://stock.noler.com/us/stock/gsk/gains-losses-recognised-in-profit-or-loss-fair-value-measurement-entitys-own-equity-instruments https://stock.noler.com/us/stock/gsk/gains-on-disposals-of-investments https://stock.noler.com/us/stock/gsk/goodwill https://stock.noler.com/us/stock/gsk/goodwill-recognised-as-of-acquisition-date https://stock.noler.com/us/stock/gsk/graph https://stock.noler.com/us/stock/gsk/gross-finance-lease-obligations https://stock.noler.com/us/stock/gsk/gross-margin https://stock.noler.com/us/stock/gsk/gross-profit https://stock.noler.com/us/stock/gsk/hedging-instrument-assets https://stock.noler.com/us/stock/gsk/hedging-instrument-liabilities https://stock.noler.com/us/stock/gsk/identifiable-assets-acquired-liabilities-assumed https://stock.noler.com/us/stock/gsk/identifiable-intangible-assets-recognised-as-of-acquisition-date https://stock.noler.com/us/stock/gsk/impairment-loss https://stock.noler.com/us/stock/gsk/impairment-loss-recognised-in-profit-or-loss https://stock.noler.com/us/stock/gsk/impairment-loss-recognised-in-profit-or-loss-goodwill https://stock.noler.com/us/stock/gsk/impairment-loss-recognised-in-profit-or-loss-intangible-assets-and-goodwill https://stock.noler.com/us/stock/gsk/impairment-loss-recognised-in-profit-or-loss-intangible-assets-other-than-goodwill https://stock.noler.com/us/stock/gsk/impairment-loss-recognised-in-profit-or-loss-property-plant-and-equipment https://stock.noler.com/us/stock/gsk/impairment-loss-recognised-in-profit-or-loss-rightofuse-assets https://stock.noler.com/us/stock/gsk/impairment-loss-reversal-of-impairment-loss-recognised-in-profit-or-loss https://stock.noler.com/us/stock/gsk/included-in-etf https://stock.noler.com/us/stock/gsk/income-from-attributable-to-owners-of-parent https://stock.noler.com/us/stock/gsk/income-from-discontinued-operations-attributable-to-owners-of-parent https://stock.noler.com/us/stock/gsk/income-tax-expense https://stock.noler.com/us/stock/gsk/income-tax-relating-to-cash-flow-hedges-of-other-comprehensive-income https://stock.noler.com/us/stock/gsk/income-tax-relating-to-financial-assets-measured-at-fair-value-through-other-comprehensive-income https://stock.noler.com/us/stock/gsk/income-tax-relating-to-investments-in-equity-instruments-of-other-comprehensive-income https://stock.noler.com/us/stock/gsk/income-tax-relating-to-remeasurements-of-defined-benefit-plans-of-other-comprehensive-income https://stock.noler.com/us/stock/gsk/income-taxes-paid-classified-as-operating-activities https://stock.noler.com/us/stock/gsk/income-taxes-paid-refund-classified-as-operating-activities https://stock.noler.com/us/stock/gsk/increase-decrease-in-cash-and-cash-equivalents-before-effect-of-exchange-rate-changes https://stock.noler.com/us/stock/gsk/increase-decrease-in-contingent-liabilities-recognised-in-business-combination https://stock.noler.com/us/stock/gsk/increase-decrease-through-business-combinations-and-disposals-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/gsk/increase-decrease-through-business-combinations-deferred-tax-liability-asset https://stock.noler.com/us/stock/gsk/increase-decrease-through-change-in-discount-rate-other-provisions https://stock.noler.com/us/stock/gsk/increase-decrease-through-changes-in-foreign-exchange-rates-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/gsk/increase-decrease-through-disposal-of-subsidiary https://stock.noler.com/us/stock/gsk/increase-decrease-through-effect-of-changes-in-foreign-exchange-rates-liabilities-arising-from-financing-activities https://stock.noler.com/us/stock/gsk/increase-decrease-through-financing-cash-flows-liabilities-arising-from-financing-activities https://stock.noler.com/us/stock/gsk/increase-decrease-through-foreign-exchange-financial-assets https://stock.noler.com/us/stock/gsk/increase-decrease-through-net-exchange-differences-deferred-tax-liability-asset https://stock.noler.com/us/stock/gsk/increase-decrease-through-net-exchange-differences-other-provisions https://stock.noler.com/us/stock/gsk/increase-decrease-through-net-exchange-differences-rightofuse-assets https://stock.noler.com/us/stock/gsk/increase-decrease-through-other-changes-liabilities-arising-from-financing-activities https://stock.noler.com/us/stock/gsk/increase-decrease-through-other-distributions-to-owners https://stock.noler.com/us/stock/gsk/increase-decrease-through-share-based-payment-transactions https://stock.noler.com/us/stock/gsk/increase-decrease-through-time-value-of-money-adjustment-other-provisions https://stock.noler.com/us/stock/gsk/increase-decrease-through-transfers-and-other-changes-equity https://stock.noler.com/us/stock/gsk/increase-decrease-through-transfers-and-other-changes-other-provisions https://stock.noler.com/us/stock/gsk/increase-decrease-through-transfers-intangible-assets-other-than-goodwill https://stock.noler.com/us/stock/gsk/increase-decrease-through-transfers-rightofuse-assets https://stock.noler.com/us/stock/gsk/insider-transactions https://stock.noler.com/us/stock/gsk/intangible-assets-other-than-goodwill https://stock.noler.com/us/stock/gsk/interest-expense https://stock.noler.com/us/stock/gsk/interest-expense-for-financial-liabilities-not-at-fair-value-through-profit-or-loss https://stock.noler.com/us/stock/gsk/interest-expense-income-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/gsk/interest-expense-on-financial-liabilities-designated-at-fair-value-through-profit-or-loss https://stock.noler.com/us/stock/gsk/interest-expense-on-lease-liabilities https://stock.noler.com/us/stock/gsk/interest-income-for-financial-assets-measured-at-amortised-cost https://stock.noler.com/us/stock/gsk/interest-income-on-available-for-sale-financial-assets https://stock.noler.com/us/stock/gsk/interest-income-on-cash-and-cash-equivalents https://stock.noler.com/us/stock/gsk/interest-income-on-financial-assets-designated-at-fair-value-through-profit-or-loss https://stock.noler.com/us/stock/gsk/interest-income-on-loans-and-receivables https://stock.noler.com/us/stock/gsk/interest-paid-classified-as-financing-activities https://stock.noler.com/us/stock/gsk/interest-payable https://stock.noler.com/us/stock/gsk/interest-receivable https://stock.noler.com/us/stock/gsk/interest-received-classified-as-investing-activities https://stock.noler.com/us/stock/gsk/inventories https://stock.noler.com/us/stock/gsk/inventory-recognised-as-of-acquisition-date https://stock.noler.com/us/stock/gsk/inventory-writedown-2011 https://stock.noler.com/us/stock/gsk/investment-accounted-for-using-equity-method https://stock.noler.com/us/stock/gsk/investments-in-subsidiaries-joint-ventures-and-associates https://stock.noler.com/us/stock/gsk/investments-other-than-investments-accounted-for-using-equity-method https://stock.noler.com/us/stock/gsk/iran-activity-notices-irannotice https://stock.noler.com/us/stock/gsk/issue-of-equity https://stock.noler.com/us/stock/gsk/issued-capital https://stock.noler.com/us/stock/gsk/key-management-personnel-compensation https://stock.noler.com/us/stock/gsk/key-management-personnel-compensation-postemployment-benefits https://stock.noler.com/us/stock/gsk/key-management-personnel-compensation-share-based-payment https://stock.noler.com/us/stock/gsk/key-management-personnel-compensation-shortterm-employee-benefits https://stock.noler.com/us/stock/gsk/late-filing-notices-nt-10-k https://stock.noler.com/us/stock/gsk/lease-commitments-for-shortterm-leases-for-which-recognition-exemption-has-been-used https://stock.noler.com/us/stock/gsk/lease-liabilities https://stock.noler.com/us/stock/gsk/legal-proceedings-provision https://stock.noler.com/us/stock/gsk/liabilities-arising-from-financing-activities https://stock.noler.com/us/stock/gsk/liabilities-included-in-disposal-groups-classified-as-held-for-sale https://stock.noler.com/us/stock/gsk/liability-asset-of-defined-benefit-plans https://stock.noler.com/us/stock/gsk/longterm-borrowings https://stock.noler.com/us/stock/gsk/market-cap https://stock.noler.com/us/stock/gsk/material-contracts https://stock.noler.com/us/stock/gsk/maximum-exposure-to-credit-risk https://stock.noler.com/us/stock/gsk/minimum-lease-payments-payable-under-noncancellable-operating-lease https://stock.noler.com/us/stock/gsk/minimum-operating-lease-payments https://stock.noler.com/us/stock/gsk/miscellaneous-other-operating-income https://stock.noler.com/us/stock/gsk/net-assets-liabilities https://stock.noler.com/us/stock/gsk/net-debt https://stock.noler.com/us/stock/gsk/net-fee-amt https://stock.noler.com/us/stock/gsk/net-margin https://stock.noler.com/us/stock/gsk/new-liabilities-contingent-liabilities-recognised-in-business-combination https://stock.noler.com/us/stock/gsk/news https://stock.noler.com/us/stock/gsk/nominal-amount-of-hedging-instrument https://stock.noler.com/us/stock/gsk/noncontrolling-interests https://stock.noler.com/us/stock/gsk/noncurrent-accrued-income-other-than-noncurrent-contract-assets https://stock.noler.com/us/stock/gsk/noncurrent-assets https://stock.noler.com/us/stock/gsk/noncurrent-assets-or-disposal-groups-classified-as-held-for-sale https://stock.noler.com/us/stock/gsk/noncurrent-assets-or-disposal-groups-classified-as-held-for-sale-or-as-held-for-distribution-to-owners https://stock.noler.com/us/stock/gsk/noncurrent-assets-other-than-financial-instruments-deferred-tax-assets-postemployment-benefit-assets-and-rights-arising-under-insurance-contracts https://stock.noler.com/us/stock/gsk/noncurrent-deferred-income-other-than-noncurrent-contract-liabilities https://stock.noler.com/us/stock/gsk/noncurrent-derivative-financial-assets https://stock.noler.com/us/stock/gsk/noncurrent-derivative-financial-liabilities https://stock.noler.com/us/stock/gsk/noncurrent-financial-liabilities-at-fair-value-through-profit-or-loss https://stock.noler.com/us/stock/gsk/noncurrent-investments-other-than-investments-accounted-for-using-equity-method https://stock.noler.com/us/stock/gsk/noncurrent-lease-liabilities https://stock.noler.com/us/stock/gsk/noncurrent-liabilities https://stock.noler.com/us/stock/gsk/noncurrent-provisions-for-employee-benefits https://stock.noler.com/us/stock/gsk/noncurrent-recognised-assets-defined-benefit-plan https://stock.noler.com/us/stock/gsk/number-of-shares-authorised https://stock.noler.com/us/stock/gsk/number-of-shares-issued-and-fully-paid https://stock.noler.com/us/stock/gsk/oci-before-tax-gains-losses-from-investments-in-equity-instruments https://stock.noler.com/us/stock/gsk/oci-before-tax-gains-losses-on-remeasurements-of-defined-benefit-plans https://stock.noler.com/us/stock/gsk/oci-net-of-tax-exchange-differences-on-translation https://stock.noler.com/us/stock/gsk/oci-net-of-tax-gains-losses-from-investments-in-equity-instruments https://stock.noler.com/us/stock/gsk/oci-that-will-be-reclassified-to-profit-or-loss-net-of-tax https://stock.noler.com/us/stock/gsk/oci-that-will-not-be-reclassified-to-profit-or-loss-net-of-tax https://stock.noler.com/us/stock/gsk/onerous-contracts-provision https://stock.noler.com/us/stock/gsk/operating-margin https://stock.noler.com/us/stock/gsk/options-activity https://stock.noler.com/us/stock/gsk/other-adjustments-to-reconcile-profit-loss https://stock.noler.com/us/stock/gsk/other-cash-payments-to-acquire-equity-or-debt-instruments-of-other-entities-classified-as-investing-activities https://stock.noler.com/us/stock/gsk/other-cash-payments-to-acquire-interests-in-joint-ventures-classified-as-investing-activities https://stock.noler.com/us/stock/gsk/other-cash-receipts-from-sales-of-equity-or-debt-instruments-of-other-entities-classified-as-investing-activities https://stock.noler.com/us/stock/gsk/other-cash-receipts-from-sales-of-interests-in-joint-ventures-classified-as-investing-activities https://stock.noler.com/us/stock/gsk/other-comprehensive-income https://stock.noler.com/us/stock/gsk/other-current-financial-assets https://stock.noler.com/us/stock/gsk/other-current-financial-liabilities https://stock.noler.com/us/stock/gsk/other-current-payables https://stock.noler.com/us/stock/gsk/other-finance-income https://stock.noler.com/us/stock/gsk/other-finance-income-cost https://stock.noler.com/us/stock/gsk/other-income https://stock.noler.com/us/stock/gsk/other-income-expense-from-subsidiaries-jointly-controlled-entities-and-associates https://stock.noler.com/us/stock/gsk/other-inflows-outflows-of-cash-classified-as-financing-activities https://stock.noler.com/us/stock/gsk/other-inflows-outflows-of-cash-classified-as-investing-activities https://stock.noler.com/us/stock/gsk/other-longterm-provisions https://stock.noler.com/us/stock/gsk/other-material-noncash-items https://stock.noler.com/us/stock/gsk/other-noncurrent-assets https://stock.noler.com/us/stock/gsk/other-noncurrent-financial-liabilities https://stock.noler.com/us/stock/gsk/other-noncurrent-liabilities https://stock.noler.com/us/stock/gsk/other-noncurrent-payables https://stock.noler.com/us/stock/gsk/other-noncurrent-receivables https://stock.noler.com/us/stock/gsk/other-operating-income-expense https://stock.noler.com/us/stock/gsk/other-provisions https://stock.noler.com/us/stock/gsk/other-receivables https://stock.noler.com/us/stock/gsk/other-reserves https://stock.noler.com/us/stock/gsk/other-shortterm-provisions https://stock.noler.com/us/stock/gsk/other-tangible-or-intangible-assets-transferred https://stock.noler.com/us/stock/gsk/other-tax-effects-for-reconciliation-between-accounting-profit-and-tax-expense-income https://stock.noler.com/us/stock/gsk/other-tax-rate-effects-for-reconciliation-between-accounting-profit-and-tax-expense-income https://stock.noler.com/us/stock/gsk/outstanding-bonds https://stock.noler.com/us/stock/gsk/par-value-per-share https://stock.noler.com/us/stock/gsk/past-service-cost-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/gsk/patents-active https://stock.noler.com/us/stock/gsk/payments-from-changes-in-ownership-interests-in-subsidiaries https://stock.noler.com/us/stock/gsk/payments-of-finance-lease-liabilities-classified-as-financing-activities https://stock.noler.com/us/stock/gsk/payments-of-lease-liabilities-classified-as-financing-activities https://stock.noler.com/us/stock/gsk/payments-to-acquire-or-redeem-entitys-shares https://stock.noler.com/us/stock/gsk/pb-ratio https://stock.noler.com/us/stock/gsk/pe-ratio https://stock.noler.com/us/stock/gsk/portion-of-consideration-paid-received-consisting-of-cash-and-cash-equivalents https://stock.noler.com/us/stock/gsk/postemployment-benefit-expense-defined-benefit-plans https://stock.noler.com/us/stock/gsk/postemployment-benefit-expense-defined-contribution-plans https://stock.noler.com/us/stock/gsk/postemployment-benefit-expense-in-profit-or-loss https://stock.noler.com/us/stock/gsk/pre-tax-margin https://stock.noler.com/us/stock/gsk/preferred-shares https://stock.noler.com/us/stock/gsk/prepayments https://stock.noler.com/us/stock/gsk/previous-etf-holding-it https://stock.noler.com/us/stock/gsk/price-fcf-ratio https://stock.noler.com/us/stock/gsk/proceeds-from-contributions-of-noncontrolling-interests https://stock.noler.com/us/stock/gsk/proceeds-from-disposal-of-noncurrent-assets-or-disposal-groups-classified-as-held-for-sale-and-discontinued-operations https://stock.noler.com/us/stock/gsk/proceeds-from-issuing-shares https://stock.noler.com/us/stock/gsk/proceeds-from-noncurrent-borrowings https://stock.noler.com/us/stock/gsk/proceeds-from-sales-of-intangible-assets-classified-as-investing-activities https://stock.noler.com/us/stock/gsk/proceeds-from-sales-of-interests-in-associates https://stock.noler.com/us/stock/gsk/proceeds-from-sales-of-investments-accounted-for-using-equity-method https://stock.noler.com/us/stock/gsk/proceeds-from-sales-of-property-plant-and-equipment-classified-as-investing-activities https://stock.noler.com/us/stock/gsk/profit-breakdown https://stock.noler.com/us/stock/gsk/profit-loss https://stock.noler.com/us/stock/gsk/profit-loss-attributable-to-noncontrolling-interests https://stock.noler.com/us/stock/gsk/profit-loss-attributable-to-owners-of-parent https://stock.noler.com/us/stock/gsk/profit-loss-before-tax https://stock.noler.com/us/stock/gsk/profit-loss-from https://stock.noler.com/us/stock/gsk/profit-loss-from-attributable-to-noncontrolling-interests https://stock.noler.com/us/stock/gsk/profit-loss-from-discontinued-operations https://stock.noler.com/us/stock/gsk/profit-loss-from-discontinued-operations-attributable-to-noncontrolling-interests https://stock.noler.com/us/stock/gsk/profit-loss-from-operating-activities https://stock.noler.com/us/stock/gsk/profit-loss-of-acquiree https://stock.noler.com/us/stock/gsk/profits-losses-on-disposal-of-investments-and-changes-in-value-of-investments https://stock.noler.com/us/stock/gsk/property-plant-and-equipment https://stock.noler.com/us/stock/gsk/property-plant-and-equipment-recognised-as-of-acquisition-date https://stock.noler.com/us/stock/gsk/provision-used-other-provisions https://stock.noler.com/us/stock/gsk/provisions https://stock.noler.com/us/stock/gsk/ps-ratio https://stock.noler.com/us/stock/gsk/purchase-of-intangible-assets-classified-as-investing-activities https://stock.noler.com/us/stock/gsk/purchase-of-interests-in-investments-accounted-for-using-equity-method https://stock.noler.com/us/stock/gsk/purchase-of-property-plant-and-equipment-classified-as-investing-activities https://stock.noler.com/us/stock/gsk/purchase-of-treasury-shares https://stock.noler.com/us/stock/gsk/quick-ratio https://stock.noler.com/us/stock/gsk/rated-credit-exposures https://stock.noler.com/us/stock/gsk/raw-materials-and-consumables-used https://stock.noler.com/us/stock/gsk/receivables-from-taxes-other-than-income-tax https://stock.noler.com/us/stock/gsk/reclassification-adjustments-on-available-for-sale-financial-assets-before-tax https://stock.noler.com/us/stock/gsk/reclassification-adjustments-on-cash-flow-hedges-before-tax https://stock.noler.com/us/stock/gsk/reclassification-adjustments-on-cash-flow-hedges-net-of-tax https://stock.noler.com/us/stock/gsk/reclassification-adjustments-on-exchange-differences-on-translation-net-of-tax https://stock.noler.com/us/stock/gsk/repayments-of-bonds-notes-and-debentures https://stock.noler.com/us/stock/gsk/repayments-of-borrowings-classified-as-financing-activities https://stock.noler.com/us/stock/gsk/repayments-of-current-borrowings https://stock.noler.com/us/stock/gsk/repayments-of-noncurrent-borrowings https://stock.noler.com/us/stock/gsk/research-and-development https://stock.noler.com/us/stock/gsk/reserve-of-exchange-differences-on-translation https://stock.noler.com/us/stock/gsk/retained-earnings https://stock.noler.com/us/stock/gsk/return-on-plan-assets-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/gsk/return-on-tangible-equity https://stock.noler.com/us/stock/gsk/revenue https://stock.noler.com/us/stock/gsk/revenue-and-operating-income https://stock.noler.com/us/stock/gsk/revenue-breakdown https://stock.noler.com/us/stock/gsk/revenue-from-performance-obligations-satisfied-or-partially-satisfied-in-previous-periods https://stock.noler.com/us/stock/gsk/revenue-from-rendering-of-services https://stock.noler.com/us/stock/gsk/revenue-from-royalties https://stock.noler.com/us/stock/gsk/revenue-from-sale-of-goods https://stock.noler.com/us/stock/gsk/reversal-of-impairment-loss-recognised-in-profit-or-loss https://stock.noler.com/us/stock/gsk/reversal-of-impairment-loss-recognised-in-profit-or-loss-property-plant-and-equipment https://stock.noler.com/us/stock/gsk/reversal-of-impairment-loss-recognised-in-profit-or-loss-rightofuse-assets https://stock.noler.com/us/stock/gsk/reversal-of-inventory-writedown https://stock.noler.com/us/stock/gsk/reversal-of-provisions-for-cost-of-restructuring https://stock.noler.com/us/stock/gsk/rightofuse-assets https://stock.noler.com/us/stock/gsk/rightofuse-assets-increase-decrease-in-revaluation-surplus https://stock.noler.com/us/stock/gsk/roa https://stock.noler.com/us/stock/gsk/roe https://stock.noler.com/us/stock/gsk/roi https://stock.noler.com/us/stock/gsk/scorecard https://stock.noler.com/us/stock/gsk/sec-comment-letters-upload https://stock.noler.com/us/stock/gsk/sec-enforcement-actions https://stock.noler.com/us/stock/gsk/sec-filings-10-q https://stock.noler.com/us/stock/gsk/sec-filings-25-nse https://stock.noler.com/us/stock/gsk/sec-filings-8-k https://stock.noler.com/us/stock/gsk/sec-filings-px14a6g https://stock.noler.com/us/stock/gsk/sec-filings-s-4 https://stock.noler.com/us/stock/gsk/secondary-offerings https://stock.noler.com/us/stock/gsk/sga-expense https://stock.noler.com/us/stock/gsk/share-of-oci-of-associates-and-joint-ventures-accounted-for-using-equity-method-that-will-be-reclassified-to-profit-or-loss-net-of-tax https://stock.noler.com/us/stock/gsk/share-of-profit-loss-of-associates-and-joint-ventures-accounted-for-using-equity-method https://stock.noler.com/us/stock/gsk/share-premium https://stock.noler.com/us/stock/gsk/shares-outstanding https://stock.noler.com/us/stock/gsk/short-sale-volume https://stock.noler.com/us/stock/gsk/shortterm-borrowings https://stock.noler.com/us/stock/gsk/shortterm-deposits-classified-as-cash-equivalents https://stock.noler.com/us/stock/gsk/shortterm-legal-proceedings-provision https://stock.noler.com/us/stock/gsk/social-security-contributions https://stock.noler.com/us/stock/gsk/stock-issued https://stock.noler.com/us/stock/gsk/stock-splits https://stock.noler.com/us/stock/gsk/sublease-payments-recognised-as-expense https://stock.noler.com/us/stock/gsk/subsidiaries https://stock.noler.com/us/stock/gsk/tax-effect-from-change-in-tax-rate https://stock.noler.com/us/stock/gsk/tax-effect-of-foreign-tax-rates https://stock.noler.com/us/stock/gsk/tax-expense-income-at-applicable-tax-rate https://stock.noler.com/us/stock/gsk/tax-rate-effect-from-change-in-tax-rate https://stock.noler.com/us/stock/gsk/tax-rate-effect-of-foreign-tax-rates https://stock.noler.com/us/stock/gsk/tax-rate-effect-of-tax-losses https://stock.noler.com/us/stock/gsk/termination-benefits-expense https://stock.noler.com/us/stock/gsk/total-assets https://stock.noler.com/us/stock/gsk/total-liabilities https://stock.noler.com/us/stock/gsk/trade-and-other-current-payables https://stock.noler.com/us/stock/gsk/trade-and-other-current-receivables https://stock.noler.com/us/stock/gsk/trade-and-other-payables-recognised-as-of-acquisition-date https://stock.noler.com/us/stock/gsk/trade-and-other-payables-to-trade-suppliers https://stock.noler.com/us/stock/gsk/trade-and-other-receivables https://stock.noler.com/us/stock/gsk/trade-receivables https://stock.noler.com/us/stock/gsk/treasury-shares https://stock.noler.com/us/stock/gsk/ttl-fee-amt https://stock.noler.com/us/stock/gsk/ttl-offset-amt https://stock.noler.com/us/stock/gsk/ttl-prevsly-pd-amt https://stock.noler.com/us/stock/gsk/ttl-tx-valtn https://stock.noler.com/us/stock/gsk/unused-provision-reversed-other-provisions https://stock.noler.com/us/stock/gsk/unused-tax-losses-for-which-no-deferred-tax-asset-recognised https://stock.noler.com/us/stock/gsk/wages-and-salaries https://stock.noler.com/us/stock/gsk/weighted-average-lessees-incremental-borrowing-rate-applied-to-lease-liabilities-recognised-at-date-of-initial-application-of-ifrs-16 https://stock.noler.com/us/stock/gsk/weighted-average-shares https://stock.noler.com/us/stock/gsk/work-in-progress https://stock.noler.com/us/stock/gsk/writedowns-reversals-of-property-plant-and-equipment